Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Novartis - NIS793 (Details)

v3.22.4
Licensing and Other Arrangements - Novartis - NIS793 (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 30, 2015
USD ($)
item
Oct. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Sep. 30, 2015
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Licensing and other arrangements                
Revenue from contracts with customers         $ 4,150 $ 36,518    
Novartis Note                
Licensing and other arrangements                
Reduction in debt obligation     $ 7,300          
Novartis International | License Agreement                
Licensing and other arrangements                
Agreement termination prior written notice period 180 days              
Number of performance obligations | item 1              
Cash payment received     17,700         $ 37,000
Revenue from contracts with customers   $ 35,000 $ 25,000   0 35,000 $ 10,000 $ 37,000
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 480,000     $ 480,000 410,000      
Royalty payment period       10 years        
Contract assets         0 0    
Contract liabilities         0 0    
Capitalized contract costs         $ 0 $ 0